Stock Analiz

LifeMD, Inc. LFMD

Medical/Nursing Services · data as of November 13, 2026

$2.19Market cap $106M
Open the interactive analysis →

LifeMD, Inc. (LFMD) is a healthcare company listed in the US with a market value of about $106M. In the twelve months to September 30, 2026 it had revenue of $189M and net income of $400420, a net margin of 0.2%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a P/E of 264.1, 5-year revenue growth of 39% a year, a 5-year average ROIC of -115%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

About LifeMD

LifeMD is listed in the US and classified in medical/nursing services. Revenue went from $714158 in 2014 to $194M in 2025, growth of about 66.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 46% over three years (dilution for shareholders).

Score: 1.8 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns2/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Pays a dividend

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)264.1
Forward P/E30.3
P/FCF—
P/S0.6
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-10.6%
Shareholder yield0.2%
Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)25.3%
Revenue growth (5 yrs, per year)39.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-24.8%
ROIC (5-yr avg.)-114.7%
Profitable years (of last 10)1
Years paying a dividend6

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$189M$194M$155M$153M$119M$93M$37M$12M$8M$5M$5M
Net income$400420$14M-$21M-$21M-$46M-$61M-$59M-$3M-$1M-$1M-$1M
Free cash flow-$11M$6M$16M$9M-$23M-$33M—————
EPS (diluted)$0.01$0.25$-0.60$-0.70$-1.57$-2.29$-4.44$-0.32$-0.25$-0.15$-0.15
Net margin0.2%7.4%-13.8%-13.5%-38.2%-65.6%-157.3%-25.2%-14.9%-24.1%-21.1%
ROIC—-20.5%-212.8%-51.0%—-174.5%——-140.0%-79.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $6.88, 213% above the current price; targets range from $3.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.34 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is LifeMD’s P/E ratio?

About 264.1, based on the last twelve months of diluted earnings per share (forward P/E about 30.3).

Is LifeMD stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does LifeMD pay a dividend?

Not currently.

Is LifeMD a good stock to buy?

We do not give buy or sell advice. LifeMD scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.